The estimated Net Worth of Jeffrey Bacha is at least $85.4 Thousand dollars as of 6 October 2017. Jeffrey Bacha owns over 10,000 units of DelMar Pharmaceuticals stock worth over $85,354 and over the last 11 years Jeffrey sold DMPI stock worth over $0.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Jeffrey Bacha DMPI stock SEC Form 4 insiders trading
Jeffrey has made over 18 trades of the DelMar Pharmaceuticals stock since 2014, according to the Form 4 filled with the SEC. Most recently Jeffrey bought 10,000 units of DMPI stock worth $8,700 on 6 October 2017.
The largest trade Jeffrey's ever made was buying 50,000 units of DelMar Pharmaceuticals stock on 16 July 2015 worth over $30,000. On average, Jeffrey trades about 4,806 units every 44 days since 2013. As of 6 October 2017 Jeffrey still owns at least 63,697 units of DelMar Pharmaceuticals stock.
You can see the complete history of Jeffrey Bacha stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Jeffrey Bacha's mailing address?
Jeffrey's mailing address filed with the SEC is SUITE 720-999 WEST BROADWAY, , VANCOUVER, A1, V5Z 1K5.
Insiders trading at DelMar Pharmaceuticals
Over the last 11 years, insiders at DelMar Pharmaceuticals have traded over $104,000 worth of DelMar Pharmaceuticals stock and bought 663,835 units worth $651,854 . The most active insiders traders include John K Bell, Robert Hoffman, and Jeffrey Bacha. On average, DelMar Pharmaceuticals executives and independent directors trade stock every 46 days with the average trade being worth of $20,766. The most recent stock trade was executed by John K Bell on 13 September 2019, trading 35,000 units of DMPI stock currently worth $23,800.
What does DelMar Pharmaceuticals do?
DelMar Pharmaceuticals, Inc. is a clinical and biopharmaceutical company, which focuses on the development and commercialization of new cancer therapies. It pipeline includes the VAL-083. The company was founded by Jeffrey A. Bacha, Dennis M. Brown, and William J. Garner on June 24, 2009 and is headquartered in San Diego, CA.
What does DelMar Pharmaceuticals's logo look like?
Complete history of Jeffrey Bacha stock trades at DelMar Pharmaceuticals
DelMar Pharmaceuticals executives and stock owners
DelMar Pharmaceuticals executives and other stock owners filed with the SEC include:
-
Saiid Zarrabian,
President, Chief Executive Officer, Director -
Scott Praill,
Chief Financial Officer -
Dennis Brown,
Chief Scientific Officer -
Robert Hoffman,
Independent Chairman of the Board -
Robert Toth,
Independent Director -
Keith Murphy,
Director -
John Liatos,
Director -
Erich Mohr,
Director -
Napoleone Ferrara,
Director -
John K Bell,
Director -
Lynda Sarah Cranston,
Director -
William J Garner,
Director -
Jeffrey Bacha,
Chief Executive Officer